Rein in Sarcoma is excited to announce a $54,000 sarcoma research grant has been awarded to Case Western Reserve University.
Case Western Reserve University: Identification of new strategies to therapeutically intervene for rhabdomyosarcomas
Principal Investigator: Berkley E. Gryder, Ph.D.
This project will expand the identification of new strategies to therapeutically intervene for rhabdomyosarcomas (RMS) driven by PAX3-FOXO1 and MYCN and treat cells with different drugs, at a variety of concentrations, in order to determine how potent they are against RMS cell lines. Research will perform RNA-seq after treatment with a panel of drugs, at various concentrations/time points, to see if the potency of drugs is directly related to how well each drug can shut down the genes that are driven by PAX3-FOXO1 and MYCN. Researchers will perform epigenetic experiments, such as 3D HiChIP, to learn how these genetic alterations are changing the epigenome of the tumor cells.